Change over period: —
NSE · AJANTPHARM
AJANTA PHARM
-12.0% from the 52-week high · +33.2% above the low
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,713 full-time employees. The company went IPO on 2000-06-05. The firm provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The firm is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. The company has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The firm's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
The short version. AJANTA PHARM reported revenue of ₹1,794 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹388 crore (up 49.2% year on year). Return on equity was 23.3% in Mar 2026. Promoter holding was 63.47% in Sep 2026, down 2.79 points over 8 quarters.
1 · The price
How has the stock traded?
AJANTA PHARM trades 12.0% below its 52-week high and 33.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,794 cr.
Sep 2026 net profit of ₹388 cr.
2.4 pts higher than a year earlier.
Revenue compounded at 13.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1794 | 1626 | 1422 | 1375 | 1354 | 1303 | 1170 | 1146 |
| Net profit | 388 | 334 | 267 | 274 | 260 | 255 | 225 | 233 |
| Net margin % | 21.6 | 20.6 | 18.8 | 19.9 | 19.2 | 19.6 | 19.2 | 20.3 |
| EPS (₹) | 31.06 | 26.75 | 21.35 | 21.91 | 20.83 | 20.44 | 18.03 | 18.64 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5453 | 4648 | 4209 | 3743 | 3341 | 2890 | 2588 | 2055 |
| Net profit | 1056 | 920 | 816 | 588 | 713 | 654 | 468 | 387 |
| Net margin % | 19.4 | 19.8 | 19.4 | 15.7 | 21.3 | 22.6 | 18.1 | 18.8 |
| EPS (₹) | 84.52 | 73.68 | 64.82 | 45.89 | 55.62 | 50.38 | 35.73 | 29.57 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 23.3% in Mar 2026; debt to equity is 0.05.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 23.3 | 24.3 | 22.9 | 17.3 |
| Return on capital % | 29.4 | 30.1 | 29.9 | 21.2 |
| EBITDA margin % | 27.9 | 28.5 | 29.3 | 23.0 |
| Net margin % | 18.8 | 19.4 | 19.0 | 15.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 13.6% | 14.0% |
| Profit CAGR | 21.6% | 10.1% |
4 · The owners
Who holds it, and are they adding?
Down 2.79 pts over 8 quarters.
Down 1.63 pts over 8 quarters.
Up 4.92 pts over 8 quarters.
+52 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.26 | 66.26 | 66.26 | 66.25 | 66.25 | 66.25 | 63.48 | 63.47 | -2.79 |
| FII | 9.26 | 8.86 | 8.86 | 8.53 | 7.98 | 8.26 | 7.68 | 7.63 | -1.63 |
| DII | 17.02 | 17.48 | 17.5 | 17.9 | 18.58 | 18.37 | 21.8 | 21.94 | +4.92 |
| Public | 7.45 | 7.39 | 7.38 | 7.32 | 7.19 | 7.12 | 7.03 | 6.96 | -0.49 |
Mutual fund holdings · Oct 2026
208 schemes hold this stock
156 the month before.
- LIC MF CHILDREN’S FUND5.19% of NAV
- PGIM INDIA HEALTHCARE FUND5.16% of NAV
- UTI - Healthcare Fund4.29% of NAV
- SAMCO FLEXICAP FUND4.28% of NAV
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND4.17% of NAV
- NIPPON INDIA PHARMA FUND3.53% of NAV
- UTI Focused Fund (30 stocks)3.02% of NAV
- SAMCO ELSS TAX SAVER FUND2.89% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AJANTA PHARM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about AJANTA PHARM
What is the AJANTA PHARM share price?
AJANTA PHARM (AJANTPHARM) last closed at ₹3,268.90, down 0.15% on the day. Its 52-week range is ₹2,458.10 to ₹3,718.20.
What is the market cap of AJANTA PHARM?
AJANTA PHARM has a market capitalisation of about ₹40,878 crore. Its price-to-earnings ratio is 32.5.
How are AJANTA PHARM's latest results?
AJANTA PHARM reported revenue of ₹1,794 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹388 crore (up 49.2% year on year). Return on equity was 23.3% in Mar 2026. Promoter holding was 63.47% in Sep 2026, down 2.79 points over 8 quarters.
Who owns AJANTA PHARM?
As of Sep 2026, shareholding was: Promoter 63.47%, FII 7.63%, DII 21.94%, Public 6.96%.
How many mutual funds hold AJANTA PHARM?
208 mutual fund schemes held AJANTA PHARM in October 2026. That compares with 156 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 10 Nov 2025 · Interim Dividend - Rs. 28
- 06 Nov 2024 · Interim Dividend - Rs. 28
- 08 Feb 2024 · Interim Dividend - Rs. 26
- 04 Aug 2023 · Special Dividend - Rs. 15
- 04 Aug 2023 · Interim Dividend - Rs. 10
- 11 Nov 2022 · Interim Dividend - Rs. 7
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.